Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011

Posted:
9
September 2011

Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011 at the Crowne Plaza Chicago O'Hare Hotel. This years meeting promises to be an exciting event that will hosting a series of excellent workshops and symposia on current, relevant topics related to improving the optimal development and use of therapeutics, with a specific focus on clinical pharmacology.Richmond Pharmacologys CEO and co-founder Dr Jorg Taubel is due to present on Monday 12th September from 18h00 to 20h00, covering the following topics of discussion:

  • Alternative Methods for The Confirmation Of Assay Sensitivity In Thorough QT Studies
  • The Use of Non-invasive Blood Pressure Recording By Photoplethysmography In Early Phase Clinical Trial Studies

Furthermore, Richmond Pharmacology will be exhibiting at the meeting, if you plan to attend we welcome you to come see us at booth number 3 to learn more about our service offering and how our specialist expertise can enhance your next clinical study. If you would like to arrange a face to face meeting with Dr Taubel, please contact a member of our business development team to arrange a time at your convenience.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more